Pharmosa Biopharm Inc. (TPEX:6875)

Taiwan · Delayed Price · Currency is TWD

32.20

-0.80 (-2.42%)

Sep 8, 2026, 11:52 AM CST

Pharmosa Biopharm Financials Overview

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	53.38	67.27	167.57	314.5	-	-
Revenue Growth	-69.25%	-59.86%	-46.72%	-	-	-
Gross Profit	10.59	13.03	126.9	314.5	-	-
Operating Income	-406.79	-402.86	-218.57	-2.82	-271.53	-259.12
Net Income	-351.33	-383.85	-166.65	8.46	-266.51	-256.48
Earnings Per Share	-2.72	-2.97	-1.32	0.07	-2.70	-3.02
EPS Growth	-	-	-	-	-	-

Revenue by Geography

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
United States	53.38	67.27	167.49	-
Taiwan	-	-	0.08	314.5
Total	53.38	67.27	167.57	314.5

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	933.28	1,131	1,618	974.06	672.51	461.46
Total Debt	340.89	99.61	117.6	144.37	21.19	37.09
Net Cash (Debt)	592.39	1,032	1,501	829.69	651.32	424.37
Net Cash Growth	-50.07%	-31.26%	80.89%	27.39%	53.48%	46.28%
Net Cash Per Share	4.59	7.99	11.87	7.32	6.61	5.00

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-319.3	-357.48	-127.16	31.45	-258.31	-237.51
Capital Expenditures	-179.28	-118.7	-165.27	-81.46	-10.16	-3.06
Free Cash Flow	-498.58	-476.18	-292.43	-50.01	-268.47	-240.57
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	19.84%	19.38%	75.73%	100.00%	-	-
Operating Margin	-762.03%	-598.88%	-130.44%	-0.90%	-	-
Pretax Margin	-658.14%	-570.63%	-99.45%	2.69%	-	-
Profit Margin	-658.14%	-570.63%	-99.45%	2.69%	-	-
FCF Margin	-933.99%	-707.88%	-174.51%	-15.90%	-	-

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 8, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	-	-	-	1219.72	-	-
PS Ratio	79.86	99.60	40.75	32.80	-	-